



Divi's Laboratories Limited

Regd. Office: 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad - 500032. CIN: L24110TG1990PLC011854
Phone: 040-23786300 Fax: 040-23786460 email: mail@divislabs.com website: www.divislabs.com

Statement of Standalone & Consolidated Audited Financial Results for the Quarter and Year Ended 31st March, 2019

(₹ in Lakhs)

Particulars	STANDALONE					CONSOLIDATED	
	QUARTER ENDED			YEAR ENDED		YEAR ENDED	
	31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
Total Revenue from operations	129816	137748	113612	503624	394971	510189	402622
Net Profit / (Loss) for the period (before Tax and Exceptional items)	41038	51289	39605	183323	121936	185507	123133
Net Profit / (Loss) for the period before tax (after Exceptional items)	41038	51289	39605	183323	121936	185507	123133
Net Profit / (Loss) for the period after tax (after Exceptional items)	28935	37949	26160	133265	86958	135274	87701
Total Comprehensive Income for the period [comprising Profit / (Loss) for the period (after tax)]	28990	37965	26338	133370	87025	135239	88691
Equity Share Capital	5309	5309	5309	5309	5309	5309	5309
Other Equity				692022	590656	690406	587171
Earnings Per Share (of ₹2/- each) (not annualised) Basic & Diluted (₹)	10.90	14.29	9.85	50.20	32.76	50.96	33.04

Notes:

- The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/ Annual Financial Results are available on the Stock Exchanges Websites (www.bseindia.com and www.nseindia.com) and also available on the Company's website www.divilaboratories.com.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Board of Directors of the company has recommended a dividend of Rs.16/- per equity share of Rs.2 each (i.e., 800%), subject to approval of members.

for Divi's Laboratories Limited

Place : Hyderabad
Date : 25.05.2019

Dr. Murali K. Divi
Chairman & Managing Director